Review Article
Use of Integra for Reconstruction after Nevi Resection: A Systematic Review and Pooled Analysis of Reported Cases
Table 2
Pooled data from all 13 included studies.
| Patient | Age (yrs) | Gender | Site | Size (%TBSA) | Initial Integra take rate | Time to skin graft (weeks) | Type of skin coverage | Follow-up time (yrs) | Initial skin graft take rate | Complete wound healing | Complications |
| Schiestl et al. [8] | 2.2 | F | Face | 2 | Yes | 3.1 | STSG | 4.08 | Yes | Yes | None | 11.0 | F | Face | 3 | Yes | 3.1 | STSG | 4 | Yes | Yes | None | 8.3 | F | Trunk | 2 | Yes | 2.7 | STSG | 3.6 | Yes | Yes | None | 3.5 | F | Trunk | 10 | No | 4.3 | STSG | 0.08 | Yes | Yes | Infection | 0.6 | F | Trunk | 2 | No | 2.7 | STSG | 2.92 | Yes | Yes | No Integra take | 0.8 | M | Trunk | 12 | Yes | 2.1 | STSG | 2.35 | Yes | Yes | None | 3.8 | M | Arm | 3 | Yes | 3 | STSG | 2 | Yes | Yes | None | 2.5 | M | Leg | 3 | No | 2.7 | STSG | 1.5 | Yes | Yes | None | 1.2 | M | Face | 1 | Yes | 3.1 | STSG | 1.35 | Yes | Yes | None | 9.7 | F | Trunk | 4 | Yes | 2.9 | STSG | 1.15 | Yes | Yes | None | 2.3 | F | Arm | 4 | Yes | 2.3 | STSG | 0.75 | Yes | Yes | None | 1.5 | F | Trunk | 6 | Yes | 3 | STSG | 0.5 | Yes | Yes | None |
| Tønseth et al. [19] | 1.5 | M | Trunk | 16 | Yes | 3 | STSG | 0.2 | Yes | Yes | Regrafting |
| Ramasamy and Jeffery [9] | 17.0 | M | Trunk | 10 | Yes | 6 | STSG | 0.8 | Yes | Yes | None |
| Ozerdem et al. [10] | 6.0 | M | Trunk | 6 | Yes | — | CEA | 0.08 | Yes | Yes | None |
| Kopp et al. [11] | 44.0 | F | Trunk | 12 | Yes | 2.9 | STSG | 2.5 | Yes | Yes | None |
| Kumbla et al. [12] | 5.5 | F | Hands/arm | 2 | Yes | 3 | STSG | 1 | Yes | Yes | None | 3.7 | F | Hands/arm | 2 | Yes | 3 | STSG | 1 | Yes | Yes | None |
| Maguire et al. [13] | 0.4 | F | Trunk | 26 | Yes | — | STSG | 5 | Yes | Yes | — |
| Barcot et al. [14] | 9.0 | F | Leg/foot | 5 | Yes | 3 | STSG | 2.7 | Yes | Yes | — |
| Alrawi and Jeffery [15] | 13.0 | M | Trunk | 16 | Yes | 4 | STSG | 13 | Yes | Yes | None | 12.0 | M | Thigh/leg | 12 | Yes | 4 | STSG | 13 | Yes | Yes | None |
| Earle and Marshall [16] | 7.0 | F | Thigh | 3 | Yes | — | CEA | — | Yes | Yes | — | 8.0 | M | Trunk | 12 | Yes | — | CEA | — | Yes | Yes | — |
| Grunwaltd et al. [17] | 11.0 | M | Nose | 0.005 | Yes | — | FTSG | — | Yes | Yes | None | 7.0 | F | Nose | 0.005 | Yes | — | FTSG | — | Yes | Yes | None |
| Abai et al. [4] | 2.8 | F | Leg | 4 | Yes | 4 | STSG | 0.5 | Yes | Yes | None | 13.0 | M | Leg | 4 | Yes | 4 | STSG | 1 | Yes | Yes | None | 10.0 | F | Trunk | 4 | Yes | 4 | STSG | 2 | Yes | Yes | None | 8.0 | F | Trunk | 6 | Yes | 4 | STSG | 1.1 | Yes | Yes | None |
| Marano et al. [18] | 2.0 | M | Trunk | 3 | Yes | 2 | STSG | 1 | Yes | Yes | Hypertrophic scar |
| Totals | Mean: 7.36 yrs SD: 7.99 yrs | M: 77% F:33% | Trunk: 51.6% Extremities: 32.3% Face: 16.1% | Mean: 6.29% TBSA SD: 5.73% TBSA | 90.30% | Mean: 3.28 wks SD: 0.83 wks | STSG: 83.9% FTSG: 6.5% CEA: 9.7% | Mean: 2.56 yrs SD: 3.22 yrs | 100% | 100% | 14.8% |
|
|